Prognostic Biomarker CPEB3 and Its Associations with Immune Infiltration in Clear Cell Renal Cell Carcinoma

Overview

Journal Biomed Rep

Specialty Biochemistry

Date 2024 Mar 13

PMID 38476610

Authors

Hualan Hong

Xi Shi

Wenyong Ou

Pengju Ou

Affiliations

Soon will be listed here.

Abstract

The role and underlying mechanism of cytoplasmic polyadenylation element binding protein 3 (CPEB3) in clear cell renal cell carcinoma [ccRCC progression remain poorly characterized. The present study was designed to evaluate the role of CPEB3 in ccRCC and its clinical associations. The overall response rate of first-line therapies (ICIs combined with VEGFR-TKIs or ICI combination) for ccRCC] is 42.0-59.3%, so a number of patients with ccRCC do not benefit from these therapies. To avoid immunosurveillance and immune killing, tumor cells decrease immunogenicity and recruit immunosuppressive cells such as regulatory T cells (Tregs). Tregs inhibit the development of anti-tumor immunity, thereby hindering immune surveillance of cancer and preventing effective anti-tumor immune response in tumor-bearing hosts. The present study analyzed clinical specimens from patients ccRCC and then examined the role of CPEB3 in ccRCC via bioinformatics analysis. CPEB3 expression was significantly reduced in ccRCC compared with normal tissue and low CPEB3 expression was associated with poor overall survival. Moreover, CPEB3 expression was an independent predictor of survival. CPEB3 expression was positively associated with immune biomarkers [CD274, programmed cell death 1 ligand 2, Hepatitis a virus cellular receptor 2, Chemokine (C-X-C motif) ligand (CXCL)9, CXCL10, Inducible T cell costimulatory, CD40, CD80 and CD38] that improve the outcome of anti-tumor immune responses. CPEB3 expression in ccRCC also affected the status of 24 types of infiltrating immune cell, of which Tregs were the most significantly negatively correlated cell type. CPEB3 may serve as a prognostic biomarker in ccRCC and its mechanism may be related to the regulation of Tregs.

References

Goldman M, Craft B, Hastie M, Repecka K, McDade F, Kamath A . Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020; 38(6):675-678. PMC: 7386072. DOI: 10.1038/s41587-020-0546-8. View

Cella D, Motzer R, Suarez C, Blum S, Ejzykowicz F, Hamilton M . Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncol. 2022; 23(2):292-303. PMC: 9479564. DOI: 10.1016/S1470-2045(21)00693-8. View

Reschke R, Gajewski T . CXCL9 and CXCL10 bring the heat to tumors. Sci Immunol. 2022; 7(73):eabq6509. DOI: 10.1126/sciimmunol.abq6509. View

Walter W, Sanchez-Cabo F, Ricote M . GOplot: an R package for visually combining expression data with functional analysis. Bioinformatics. 2015; 31(17):2912-4. DOI: 10.1093/bioinformatics/btv300. View

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q . TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020; 48(W1):W509-W514. PMC: 7319575. DOI: 10.1093/nar/gkaa407. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

Choueiri T, Powles T, Burotto M, Escudier B, Bourlon M, Zurawski B . Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021; 384(9):829-841. PMC: 8436591. DOI: 10.1056/NEJMoa2026982. View

Josefowicz S, Lu L, Rudensky A . Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012; 30:531-64. PMC: 6066374. DOI: 10.1146/annurev.immunol.25.022106.141623. View

. New Treatments Emerge for RCC. Cancer Discov. 2021; 11(5):OF10. DOI: 10.1158/2159-8290.CD-NB2021-0323. View

10.

Ged Y, Markowski M, Singla N, Rowe S . The shifting treatment paradigm of metastatic renal cell carcinoma. Nat Rev Urol. 2022; 19(11):631-632. PMC: 9774042. DOI: 10.1038/s41585-022-00651-9. View

11.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

12.

Koebel C, Vermi W, Swann J, Zerafa N, Rodig S, Old L . Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007; 450(7171):903-7. DOI: 10.1038/nature06309. View

13.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

14.

Nakamura K, Smyth M . Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2019; 17(1):1-12. PMC: 6952382. DOI: 10.1038/s41423-019-0306-1. View

15.

Chen J, Li L, Liu T, Fu H, Lai Y, Lei X . CPEB3 suppresses gastric cancer progression by inhibiting ADAR1-mediated RNA editing via localizing ADAR1 mRNA to P bodies. Oncogene. 2022; 41(41):4591-4605. DOI: 10.1038/s41388-022-02454-z. View

16.

Motzer R, Alekseev B, Rha S, Porta C, Eto M, Powles T . Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021; 384(14):1289-1300. DOI: 10.1056/NEJMoa2035716. View

17.

Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

18.

Quail D, Bowman R, Akkari L, Quick M, Schuhmacher A, Huse J . The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 2016; 352(6288):aad3018. PMC: 5450629. DOI: 10.1126/science.aad3018. View

19.

Barkley D, Moncada R, Pour M, Liberman D, Dryg I, Werba G . Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment. Nat Genet. 2022; 54(8):1192-1201. PMC: 9886402. DOI: 10.1038/s41588-022-01141-9. View

20.

Yan C, Richmond A . Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy. Mol Cancer. 2021; 20(1):146. PMC: 8582157. DOI: 10.1186/s12943-021-01442-3. View